HALIFAX, Oct. 22, 2108 /PRNewswire/ - Adaptiiv, an innovative medical technology company announced today the University of Hong Kong will use 3D Bolus Software, an advanced software solution that enables the creation of customized personal medical devices using 3D printing, used primarily in the treatment of cancer. Additionally, Adaptiiv will partner with the University's department of Clinical Oncology to develop new applications.
Adaptiiv is the first company in the world to receive FDA 510k clearance for 3D printing software used in radiation oncology. Founded in 1911, The University of Hong Kong is the territory's oldest institute of higher learning and also an internationally recognized, research led, comprehensive university.
3D Bolus Software provides practitioners with a turn-key solution that enables 3D printing of patient-specific uniform thickness bolus, modulated bolus for MERT (modulated electron radiation therapy), High Dose Rate (HDR) surface brachytherapy and other potential ancillary devices. Boluses created using Adaptiiv's software conforms to the patient anatomy to improve dose and the patient experience. Patients are more comfortable through the treatment period, while set-up and production times are reduced.
"Bringing on the University of Hong Kong as both a client and a research partner extends Adaptiiv's global footprint into our seventh country," says Adaptiiv CEO, Peter Hickey. The company's software is already used in the United States, Canada, Australia, Israel, Ireland, and England.
Adaptiiv Medical Technologies Inc. (formerly 3D Bolus Inc.) is the definitive 3D technology platform for radiation oncology. Headquartered in Halifax, Nova Scotia, Canada, Adaptiiv is shaping the future of patient-specific healthcare through innovation and collaboration with leading Cancer centres throughout the world. Adaptiiv has a 510(k) clearance, is ISO 13485 certified and has received a CE Mark.
SOURCE Adaptiiv Inc